Document Detail

The ethics of drug development and promotion: the need for a wider view.
MedLine Citation:
PMID:  23047778     Owner:  NLM     Status:  In-Data-Review    
Ethical issues at the interface between the medical profession and the pharmaceutical industry have generally been approached from the vantage point of medical professionalism, with a focus on conflict of interest as the key ethical concern. Although conflicts of interest remain important, other ethical issues may be obscured unless a wider perspective is adopted. Besides medical professionalism, the ethics of the clinical therapeutic relationship, ethics of public health, and business ethics all provide additional insights.
Howard Brody
Related Documents :
24016928 - Interaction between cardiac myocytes and fibroblasts: in vivo and in vitro.
24948998 - Can hospital promotional activities be more ethical?
23278558 - Review of the 92nd annual meeting of the british association of dermatologists, 3-5 jul...
24719888 - Evidence for the use of isoflurane as a replacement for chloral hydrate anesthesia in e...
22058108 - Status, race, and money: the impact of racial hierarchy on willingness to pay.
19684558 - Assisted suicide: increased support for a change in the law.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Medical care     Volume:  50     ISSN:  1537-1948     ISO Abbreviation:  Med Care     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0230027     Medline TA:  Med Care     Country:  United States    
Other Details:
Languages:  eng     Pagination:  910-2     Citation Subset:  IM    
*Institute for the Medical Humanities †Department of Family Medicine, University of Texas Medical Branch, Galveston, TX.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Synthesis and photopolymerization kinetics of benzophenone sesamol one-component photoinitiator.
Next Document:  Impact of Part D Low-income Subsidies on Medication Patterns for Medicare Beneficiaries With Diabete...